Searchable abstracts of presentations at key conferences in endocrinology

ea0070ep347 | Pituitary and Neuroendocrinology | ECE2020

Behaviour of the long-term clinical and analytical characteristics of a series of cases with hypopituitarism

Añez Roberto , Rivas Alejandra , Carlos Percovich Juan , Atencia Jose , Weber Bettina , Brox Noemí , Miguélez María , Gonzalez Laura , Muñoz Diego , Monereo Susana , García Centeno Rogelio

Aim: To describe the clinical and analytical characteristics of patients with hypopituitarism in the Endocrinology Department.Materials and methods: This was a descriptive, retrospective study with 70 patients diagnosed with hypopituitarism in the Endocrinology Department´s outpatient consultations with a follow-up of up to 44 years. The qualitative variables were expressed in frequencies and the quantitative variables showed a normal distribution e...

ea0070aep654 | Pituitary and Neuroendocrinology | ECE2020

Our experience with lu-dotatate in patients with neuroendocrine tumors in a tertiary hospital

Munoz Diego , Carlos Percovich Hualpa Juan , Weber Bettina , Atencia Goñi José , González Fernández Laura , Miguélez González María , Brox Torrecilla Noemí , José Añez Ramos Roberto , Maricel Rivas Montenegro Alejandra , López Guerra Aurelio , Lucía Olmedilla Isishi Yoko , Ángeles Vélez Romero María , Ágreda García Javier , Picallo Pérez María , Monereo Megías Susana , García Centeno Rogelio

Introduction: Lutetium-177-DOTATATE (Lu177) is approved in patients with well-differentiated (G1 and G2) neuroendocrine tumors (NETs) positive to somatostatin receptors, progressive and unresectable or metastatic. Lu177 has been shown to increase progression-free survival and the quality of life of these patients.Material and Methods: Retrospective descriptive study of a series of 15 cases with NETs treated with Lu177. Demographic data, tumor characteris...